IL124551A - Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters - Google Patents

Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters

Info

Publication number
IL124551A
IL124551A IL12455197A IL12455197A IL124551A IL 124551 A IL124551 A IL 124551A IL 12455197 A IL12455197 A IL 12455197A IL 12455197 A IL12455197 A IL 12455197A IL 124551 A IL124551 A IL 124551A
Authority
IL
Israel
Prior art keywords
fatty acid
acid esters
aqueous suspensions
depot formulations
pharmaceutical depot
Prior art date
Application number
IL12455197A
Other languages
English (en)
Other versions
IL124551A0 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL124551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL124551A0 publication Critical patent/IL124551A0/xx
Publication of IL124551A publication Critical patent/IL124551A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL12455197A 1996-05-20 1997-05-12 Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters IL124551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (fr) 1996-05-20 1997-05-12 Suspensions aqueuses d'esters d'acides gras de 9-hydroxyrisperidone

Publications (2)

Publication Number Publication Date
IL124551A0 IL124551A0 (en) 1998-12-06
IL124551A true IL124551A (en) 2001-08-26

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12455197A IL124551A (en) 1996-05-20 1997-05-12 Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters

Country Status (37)

Country Link
US (1) US6077843A (fr)
EP (1) EP0904081B1 (fr)
JP (1) JP3274687B2 (fr)
KR (1) KR100358373B1 (fr)
CN (1) CN1093762C (fr)
AR (1) AR007194A1 (fr)
AT (1) ATE208619T1 (fr)
AU (1) AU715572B2 (fr)
BG (1) BG62684B1 (fr)
BR (1) BR9706824B8 (fr)
CA (1) CA2236691C (fr)
CY (2) CY2270B1 (fr)
CZ (1) CZ291284B6 (fr)
DE (2) DE122011100027I1 (fr)
DK (1) DK0904081T3 (fr)
EA (1) EA000536B1 (fr)
EE (1) EE03594B1 (fr)
ES (1) ES2167745T3 (fr)
FR (1) FR11C0035I2 (fr)
HR (1) HRP970276B1 (fr)
HU (2) HU224025B1 (fr)
ID (1) ID16927A (fr)
IL (1) IL124551A (fr)
LU (1) LU91842I2 (fr)
MX (1) MX9804816A (fr)
MY (1) MY126302A (fr)
NO (2) NO315931B1 (fr)
NZ (1) NZ330369A (fr)
PL (1) PL188309B1 (fr)
PT (1) PT904081E (fr)
SI (1) SI0904081T1 (fr)
SK (1) SK284013B6 (fr)
TR (1) TR199800923T2 (fr)
TW (1) TW487572B (fr)
UA (1) UA61898C2 (fr)
WO (1) WO1997044039A1 (fr)
ZA (1) ZA974331B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
DE69917000T2 (de) * 1998-02-25 2005-04-21 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
ES2255490T3 (es) 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
KR100818875B1 (ko) * 2000-08-14 2008-04-01 테바 파마슈티컬 인더스트리즈 리미티드 리스페리돈의 제조
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR100699516B1 (ko) * 2002-07-29 2007-03-26 알자 코포레이션 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2553254C (fr) * 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Preparations a liberation a long terme et procedes d'utlisation de celles-ci
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1879890A1 (fr) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation d'ester de 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl¨-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridioý1,2-a¨pyrimidin-4-one palmitate aseptique
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP2049081B1 (fr) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Systemes d'administration osmotiques et ensembles pistons
JP5315336B2 (ja) * 2007-04-19 2013-10-16 又欣 李 精神疾患治療用の新規化合物とその調剤及び使用
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
BRPI0821408A2 (pt) * 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
WO2009089076A2 (fr) * 2008-01-10 2009-07-16 Teva Pharmaceutical Industries Ltd. Procédés de préparation et de purification de palmitate de palipéridone
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR101760953B1 (ko) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
MX2012005083A (es) 2009-10-30 2012-09-28 Janssen Pharmaceutica Nv Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada.
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2683717B1 (fr) * 2011-05-31 2016-05-25 Ramamohan Rao, Davuluri Préparation de 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-pipéridinyl)-6, 7, 8, 9-tétrahydro-9-hydroxy-2-méthyl-4h-pyrido [ 1, 2-a]-pyrimidin-4-one (palepéridone) et de palmitate de palipéridone
WO2013046225A2 (fr) * 2011-08-10 2013-04-04 Glenmark Generics Limited Procédé de préparation de palmitate de palipéridone
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016244801B2 (en) 2015-04-07 2020-06-25 Janssen Pharmaceutica Nv Dosing regimen for missed doses for long-acting injectable paliperidone esters
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
PL4025187T3 (pl) 2020-11-30 2024-04-29 Janssen Pharmaceutica Nv Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
IL303254A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
MX2023006368A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
IL303253A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release injectable formulations of paliperidone
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
WO2023021008A1 (fr) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Schémas posologiques associés à des formulations injectables de palipéridone à libération prolongée

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (fr) * 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CA2474701C (fr) * 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation de microparticules biodegradables contenant un agent biologiquement actif
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
DK0833820T3 (da) * 1995-06-06 2001-04-17 Aventis Pharma Inc Benzisoxazol- og indazolderivater som antipsykotiske midler
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
HUS1100013I1 (hu) 2017-03-28
FR11C0035I1 (fr) 2011-07-10
DE69708284T2 (de) 2002-07-25
HK1017852A1 (en) 1999-12-03
EE9800136A (et) 1998-10-15
PL327995A1 (en) 1999-01-04
JP2000513718A (ja) 2000-10-17
HU224025B1 (hu) 2005-05-30
NZ330369A (en) 2000-04-28
US6077843A (en) 2000-06-20
ZA974331B (en) 1998-11-19
KR100358373B1 (ko) 2003-02-11
EP0904081A1 (fr) 1999-03-31
NO2011015I1 (no) 2011-09-19
EA199800531A1 (ru) 1998-12-24
NO981984L (no) 1998-11-19
BR9706824B8 (pt) 2015-02-18
HUP9901319A3 (en) 1999-11-29
SK284013B6 (sk) 2004-08-03
SI0904081T1 (en) 2002-04-30
NO2011015I2 (no) 2013-03-11
DE122011100027I1 (de) 2011-11-17
PL188309B1 (pl) 2005-01-31
CY2270B1 (en) 2003-07-04
HRP970276B1 (en) 2002-04-30
EP0904081B1 (fr) 2001-11-14
MY126302A (en) 2006-09-29
CN1206347A (zh) 1999-01-27
EE03594B1 (et) 2002-02-15
HUP9901319A2 (hu) 1999-08-30
LU91842I2 (fr) 2011-09-20
AR007194A1 (es) 1999-10-13
CA2236691A1 (fr) 1997-11-27
FR11C0035I2 (fr) 2013-08-16
NO981984D0 (no) 1998-04-30
KR19990067603A (ko) 1999-08-25
PT904081E (pt) 2002-04-29
DK0904081T3 (da) 2002-02-25
NO315931B1 (no) 2003-11-17
BG102443A (en) 1999-06-30
ES2167745T3 (es) 2002-05-16
HRP970276A2 (en) 1998-04-30
WO1997044039A1 (fr) 1997-11-27
CZ140198A3 (cs) 1999-04-14
CZ291284B6 (cs) 2003-01-15
TR199800923T2 (xx) 1999-09-21
ID16927A (id) 1997-11-20
SK62098A3 (en) 2000-04-10
CN1093762C (zh) 2002-11-06
BG62684B1 (bg) 2000-05-31
EA000536B1 (ru) 1999-10-28
DE69708284D1 (de) 2001-12-20
BR9706824A (pt) 1999-03-23
AU715572B2 (en) 2000-02-03
CA2236691C (fr) 2007-01-02
AU2955997A (en) 1997-12-09
MX9804816A (es) 1998-10-31
CY2011011I2 (el) 2016-12-14
ATE208619T1 (de) 2001-11-15
JP3274687B2 (ja) 2002-04-15
TW487572B (en) 2002-05-21
UA61898C2 (en) 2003-12-15
IL124551A0 (en) 1998-12-06
CY2011011I1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
IL124551A (en) Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters
IL136135A (en) Aqueous suspensions of submicron 9- hydroxyrisperidone fatty acid esters
HUP0101653A3 (en) Fatty acid derivatives of bile acids and bile acid derivatives and pharmaceutical compositions thereof
ZA929147B (en) Fatty acid esters of alkoxylated isethionic acid
HUP0202342A3 (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
PL331700A1 (en) Method of obtaining fatty acid esters
PL318132A1 (en) Aqueous preparations of risperidone
IL103932A0 (en) Fatty acid derivatives and pharmaceutical compositions containing them
ZA945189B (en) Sulfonation of fatty acid esters
AU2111095A (en) Salts of omega-3-polyunsaturated fatty acids and pharmaceutical formulations containing them
AU4560297A (en) Pharmaceutical microspheres of valproic acid for oral administration
IL115594A (en) Preparation of alpha-tertiary carboxylic acid esters
HUP9700810A3 (en) Acids and esters of diosmetin and pharmaceutical compositions containing them
AU6557800A (en) Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids
AU6557700A (en) Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids
IL122919A (en) Preparation of 1-alkyl-pyrazole-5- carboxylic acid esters
AU6498298A (en) Mixtures of alkylphosphoric acid esters and their use as cosmetic and pharmaceutical emulsifiers
NZ223684A (en) Guanidine carboxylic acid esters and pharmaceutical compositions
AU7915901A (en) Preparation of dicarboxylic acid monoesters from cyanocarboxylic acid esters

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired